W. R. Berkley

WRB · NYSE

$73.15−$0.93 (−1.26%)TodayMarket closed ·
Prev close $74.08

WRB analyst rating

HoldConsensus of 15 analysts over the last 12 months. 20% rate it a buy.
  • Strong buy0
  • Buy3
  • Hold7
  • Underperform4
  • Sell1

12-month price target · 21 analysts

Average $69.64 (−4.8% downside)

Low
$51.45
Now
$73.15
High
$87.15

Upgrades and downgrades

The latest rating actions, newest first

WRB analyst upgrades, downgrades and rating actions
FirmDateActionRating
Wells FargoOct 20, 2026MaintainsUnderweight
Evercore ISI GroupOct 20, 2026MaintainsUnderperform
MizuhoOct 20, 2026MaintainsNeutral
Wells FargoOct 12, 2026MaintainsUnderweight
MizuhoOct 7, 2026MaintainsNeutral
Cantor FitzgeraldOct 7, 2026MaintainsNeutral
Morgan StanleyOct 6, 2026MaintainsEqual-Weight
MizuhoSep 16, 2026MaintainsNeutral
UBSJul 27, 2026MaintainsNeutral
Wells FargoJul 21, 2026MaintainsUnderweight

The case for and against

Updated Oct 7, 2026

Bull case

  • WR Berkley is well positioned by its ability to generate earnings beats through both underwriting discipline and strong investment income, as shown by 2Q operating EPS of $1.27 versus $1.08 expected and underwriting income of $318 million.
  • Its insurance franchise is improving, with a 91.4% combined ratio, modest premium growth across specialty lines, and ROE from operations of 20.5% alongside book value per share rising 3% from the start of the year to $26.50.
  • The outlook is further supported by net investment income of $419 million, a reinvestment rate above its domestic book yield, and a strategy focused on niche E&S and specialty markets that should aid margin expansion as topline growth strengthens.

Bear case

WR Berkley is facing a weakening fundamental setup because its topline growth is increasingly uneven, with consolidated net premiums written up only 1% and key lines like casualty reinsurance down 14% to 15% amid marginal rate adequacy and stepped-up competition. Although the consolidated combined ratio remained sub-91%, catastrophe losses of 200 to 240 bps, a rising 28.6% expense ratio, and pressure from softer premiums in Reinsurance & Monoline Excess point to earnings volatility and less operating leverage. Long-tail reserve exposure, inflation risk, and an elevated mix of non-traditional investments add further downside risk to earnings quality and make the stock vulnerable if pricing momentum deteriorates.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.